Official publication of Rawalpindi Medical University
Varied Presentations Of Patients With Systemic Lupus Erythematosus – What Makes Pakistani Lupus Patients Different

Supplementary Files

PDF

How to Cite

1.
Manzoor MS, Mumtaz S, Maqbool F, Samar D, Adil MH, Malik J. Varied Presentations Of Patients With Systemic Lupus Erythematosus – What Makes Pakistani Lupus Patients Different. JRMC [Internet]. 2024 Mar. 16 [cited 2024 Jun. 16];28(1). Available from: http://www.journalrmc.com/index.php/JRMC/article/view/2550

Abstract

Objective: This study was conducted to characterize the clinical presentation, results of serological and immunological tests and sociodemographic factors in the Pakistani Lupus population.

Methods: This prospective, cross-sectional study was undertaken at the Clinic for Arthritis and Rheumatic Diseases, Rawalpindi Teaching Hospital, Rawalpindi, Pakistan between January 2020 and June 2023, involving adult patients with SLE (classified based on 1997 revised ACR criteria). Demographic data, clinical and laboratory features, auto-antibody profile, disease duration, treatment history and organ damage (calculated by SLICC/ACR-DI) were recorded for all patients. Descriptive statistics and logistic regression analysis were performed for statistical assessment.

Results: A total of 98 patients (94.9% females and 5.1% males) were enrolled in the study. The mean age of patients was 30.93±11.09 years while the mean duration of illness was 3.27±3.01years. The most commonly observed clinical manifestations were neuropsychiatric systemic lupus erythematosus in 84% of patients and mucocutaneous involvement (photosensitivity, mucosal ulcers, facial rash, alopecia and discoid lupus in 63.92%, 56.70%, 48.45%, 37.11% and 13.40% patients respectively). They were followed by serositis, arthralgias and renal involvement in 60.42%, 33.67% and 25% of patients respectively. Anti-nuclear antibody by indirect immunofluorescence was positive in all while anti-dsDNA was positive in 50% of patients.

Conclusions: Fatigue was the most commonly recorded symptom while Neuropsychiatric SLE was the most commonly observed systemic manifestation in the Pakistani population followed by mucocutaneous involvement, serositis, arthralgias and renal involvement. Reasons for serious manifestations at initial presentation include deficiency of healthcare professionals trained in the field of Rheumatology and lack of awareness among patients.

Keywords: Clinical profile, Systemic Lupus Erythematosus, Clinical and laboratory features, Organ damage, Pakistan

References

Suda M, Kishimoto M, Ohde S, Okada M. 2020. Validation of the 2019 ACR/EULAR classification criteria of systemic lupus erythematosus in 100 Japanese patients: a real-world setting analysis. Clin. Rheumatol. 39:1823–27

Sternhagen E, Bettendorf B, Lenert A, Lenert PS. The Role of Clinical Features and Serum Biomarkers in Identifying Patients with Incomplete Lupus Erythematosus at Higher Risk of Transitioning to Systemic Lupus Erythematosus: Current Perspectives. J Inflamm Res. 2022;15:1133-1145.

Sahoo RR, Wakhlu A, Agarwal V. Neglected tropical rheumatic diseases. Clin Rheumatol. 2022 May;41(5):1293-1304.

Skudalski L, Shahriari N, Torre K, Santiago S, Bibb L, Kodomudi V,et al. Emerging therapeutics in the management of connective tissue disease. Part I. Lupus erythematosus and Sjögren syndrome. J Am Acad Dermatol. 2022 Jul;87(1):1-18.

Emorinken A, Dic-Ijiewere MO, Erameh CO, Ugheoke AJ, Agbadaola OR, Agbebaku FO. Clinical and laboratory profile of systemic lupus erythematosus patients at a rural tertiary centre in South-South Nigeria: experience from a new rheumatology clinic. Reumatologia. 2021;59(6):402-410.

Kayser C, Dutra LA, Dos Reis-Neto ET, Castro CHM, Fritzler MJ, Andrade LEC. The Role of Autoantibody Testing in Modern Personalized Medicine. Clin Rev Allergy Immunol. 2022 Oct;63(2):251-288.

Wafa A, Hicham H, Naoufal R, Hajar K, Rachid R, Souad B,et al. Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: a study of 20 Moroccan adult patients. Clin Rheumatol. 2022 Jul;41(7):2021-2033.

Scheen M, Adedjouma A, Esteve E, Buob D, Abisror N, Planche V,et al. Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management. Autoimmun Rev. 2022 May;21(5):103072.

Khan A, Haroon M, Lashari N, Khan S, Khanum A, Asif S. Inflammatory arthritis and younger age of lupus onset are associated with the development of neuropsychiatric lupus: experience from a single centre in Pakistan. Acta Rheumatol. (2021) 8:1–7

Takeshima Y, Iwasaki Y, Nakano M, Narushima Y, Ota M, Nagafuchi Y,et al. Immune cell multi-omics analysis reveals contribution of oxidative phosphorylation to B-cell functions and organ damage of lupus. Ann Rheum Dis. 2022 Jun;81(6):845-853.

Aringer M, Costenbader K, Johnson SR. Assessing the EULAR/ACR classification criteria for patients with systemic lupus erythematosus. Expert Rev Clin Immunol. 2022 Feb;18(2):135-144.

Durcan L, O’Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. (2019) 393:2332–43.

Shamim R, Farman S, Batool S, Khan S, Raja M. Association of systemic lupus erythematosus disease activity index score with clinical and laboratory parameters in pediatric onset systemic lupus erythematosus. Pak J Med Sci. (2020) 36:467

Bingham K, DiazMartinez J, Green R, Tartaglia M, Ruttan L, Su J, et al. Longitudinal relationships between cognitive domains and Depression and anxiety symptoms in systemic lupus erythematosus. Semin Arthritis Rheum. (2021) 51:1186–92.

Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane Handbook for Systematic Reviews of Interventions. Hoboken, NJ: John Wiley & Sons; (2019). 10.1002/9781119536604

Meier A, Bodmer N, Wirth C, Bachmann L, Ribi C, Pröbstel A, et al. Neuro-psychiatric manifestations in patients with systemic lupus erythematosus: a systematic review and results from the Swiss lupus cohort study. Lupus. (2021) 30:1565–76.

Ragab S, Ibrahim A. Neuropsychiatric lupus erythematosus in a cohort of Egyptian patients. Egypt J Neurol Psychiatry Neurosurg. (2022) 58:1–7.

Meier A, Bodmer N, Wirth C, Bachmann L, Ribi C, Pröbstel A, et al. Neuro-psychiatric manifestations in patients with systemic lupus erythematosus: a systematic review and results from the Swiss lupus cohort study. Lupus. (2021) 30:1565–76.

Dima A, Jurcut C, Chasset F, Felten R, Arnaud L. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis. 2022;14:1759720X211073001.

Mukkera S, Mannem M, Chamarti K, Pillarisetty L, Vulasala SS, Alahari L,et al. Systemic Lupus Erythematosus-Associated Serositis Managed With Intravenous Belimumab: A Case Report. Cureus. 2022 Feb;14(2):e22639.

Baranyi G, Scholl C, Fazel S, Patel V, Priebe S, Mundt A. Severe mental illness and substance use disorders in prisoners in low-income and middle-income countries: a systematic review and meta-analysis of prevalence studies. Lancet Glob Health. (2019) 7:e461–71.

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Copyright (c) 2024 Muhammad Shahzad Manzoor, Shamaila Mumtaz, Faran Maqbool, Darakhshaan Samar, Muhammad Hammas Adil, Javaria Malik